Vitamin B6 in the form of pyridoxal 5'-phosphate (PLP) has been shown to inhibit in vitro platelet aggregation induced by ADP, collagen, thrombin, epinephrine and arachidonic acid (1-4). Human studies have revealed that platelet aggregation induced by ADP and epinephrine was significantly inhibited after the oral supplementation of vitamin B6 at 100mg twice per day for 15 d (5). The inhibi tion percentages of platelet aggregation by ADP and epinephrine were 48 and 41%, respectively, after a single daily oral dose of 5mg B6/kg for 4 wk (6 
RESULTS

Construction of pBLIIbCAT3
The 0.6kb fragment of the GPIIb promoter region spanning from nucleotide -546 to +45 was amplified by PCR (Fig . I) and cloned into pBLCAT3. The resulting. plasmid was pBLIIbCAT3, 4.9kb. The restriction enzyme digestion patterns (Fig. 2) confirm the correct construction of pBLIIbCAT3.
GPIIB promoter . functional assay
The promoter activity of the constructed GPIIb promoter in pBLIIbCAT3 was assayed in cultured HEL cells (Fig. 3) . CAT activity expressed in untransfected cells without TPA was assigned a value of 1.0, and the CAT activity detected in cells transfected with pBLCAT3 or pBLIIbCAT3 in the presence or absence of TPA was measured as multiples of increase as compared to the value of untransfected cells. A 32-fold increase and 4-fold increase of CAT activity were detected in cells transfected with pBLIIbCAT3 or pBLCAT3 as compared to the mock control , J Niur Sei Vitaminot 
